<DOC>
	<DOCNO>NCT02622074</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability clinical activity pembrolizumab ( MK-3475 ) combination six chemotherapy regimen neoadjuvant treatment participant triple negative breast cancer ( TNBC ) . The primary objective study : 1 ) determine safety tolerability 2 ) establish recommend Phase 2 dose six combination regimen neoadjuvant treatment participant TNBC .</brief_summary>
	<brief_title>Safety Efficacy Study Pembrolizumab ( MK-3475 ) Combination With Chemotherapy Neoadjuvant Treatment Participants With Triple Negative Breast Cancer ( TNBC ) ( MK-3475-173/KEYNOTE 173 )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Has previously untreated , locally advanced TNBC . Is able provide 2 core needle biopsy primary tumor screen central laboratory agree core needle biopsy single dose pembrolizumab treatment tumor biopsy feasible judged investigator . Has Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Has adequate organ function . Females childbearing potential must willing use adequate contraception course study 12 month last dose study drug participant receive cyclophosphamide 6 month last dose study drug participant receive cyclophosphamide . Has evidence metastatic breast cancer , concurrent bilateral invasive breast cancer , inflammatory breast cancer . Has another malignancy within last 5 year . Exceptions include basal cell carcinoma skin , squamous cell carcinoma skin undergone potentially curative surgery , situ cervical cancer . Has receive prior chemotherapy , target therapy , radiation therapy , immunotherapy target immune checkpoint , costimulatory coinhibitory pathway T cell receptor within past 12 month . Is currently participate receive study therapy , participate study investigational agent receive study therapy use investigational device within 4 week first dose study drug . Has receive live vaccine within 30 day first dose study drug . Has active autoimmune disease require systemic treatment past 2 year . Has diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose study drug . Has know history Human Immunodeficiency Virus ( HIV ) . Has know active Hepatitis B Hepatitis C. Has evidence current pneumonitis . Has history noninfectious pneumonitis require treatment steroid history interstitial lung disease . Has active infection require systemic therapy . Has significant cardiovascular disease , : History myocardial infarction , acute coronary syndrome coronary angioplasty/stenting/bypass graft within last 6 month ; Congestive heart failure ( CHF ) New York Heart Association ( NYHA ) Class IIIV history CHF NYHA class III IV Has know psychiatric substance abuse disorder would interfere cooperation requirement study . Is pregnant breastfeeding , expect conceive child within project duration study , start screen visit 120 day last dose study drug . Has know hypersensitivity component study drug analog .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PD1</keyword>
	<keyword>PD-1</keyword>
	<keyword>PDL1</keyword>
	<keyword>PD-L1</keyword>
	<keyword>Triple Negative Breast Cancer</keyword>
</DOC>